TITLE

The American Orthopaedic Association Clinical Trials Curriculum

AUTHOR(S)
Diamond, Ivan R.; Murray, Camille; Bosse, Michael J.; Heckman, James D.; Mirza, Sohail K.; Peabody, Terrance D.; Saleh, Khaled J.; Swiontkowski, Marc F.; Wright, James G.
PUB. DATE
April 2009
SOURCE
Journal of Bone & Joint Surgery, American Volume;Apr2009, Vol. 91-A Issue 4, p1007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents an overview of the rationale, objectives and design of a curriculum which was developed by the American Orthopedic Association in an effort to facilitate the advancement of clinical trials in orthopedics. An evaluation of the curriculum is offered. The importance of having well designed clinical trials which focus on orthopedics is discussed.
ACCESSION #
37614994

 

Related Articles

  • Evidence supporting platform-switching to preserve marginal bone levels not definitive. Stafford, Gary L // Evidence-Based Dentistry;Jun2012, Vol. 13 Issue 2, p56 

    Data sourcesMEDLINE, EMBASE, The Cochrane Oral Health Group's Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), UK National Research Register, Australian New Zealand Clinical Trials Registry (ANZCTR), Database of Abstracts of Reviews of Effectiveness (DARE), ISI...

  • Fully informed consent is impossible in surgical clinical trials. Bernstein, Mark // Canadian Journal of Surgery;Aug2005, Vol. 48 Issue 4, p271 

    This article reports that fully informed consent by patient is impossible in surgical clinical trials. Consent for an investigative procedure has 3 distinct but interrelated elements that are essentially the same as for purely therapeutic procedures: disclosure, capacity and voluntariness. It is...

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Clinical trial regulation in Argentina: overview and analysis of regulatory framework, use of existing tools, and researchers' perspectives to identify potential barriers. White, Lauren; Ortiz, Zulma; Cuervo, Luis G.; Reveiz, Ludovic // Pan American Journal of Public Health;Nov2011, Vol. 30 Issue 5, p445 

    Objective. To review and analyze the regulatory framework of clinical trial registration, use of existing tools (publicly accessible national/international registration databases), and users' perspectives to identify possible barriers to registration compliance by sponsors and researchers in...

  • Drugs tests on trial.  // Nature;4/20/2006, Vol. 440 Issue 7087, p970 

    The article reports on the changes to clinical trials by the Medicines and Healthcare Products Regulatory Agency in Great Britain. There were limitations of preclinical animal trials in determining the safety of drugs in humans, especially for humanized antibody drugs that are targeted at...

  • Fears rise over leaks of clinical trial results. Gewin, Virginia // Nature;9/8/2005, Vol. 437 Issue 7056, p191 

    Focuses on the possible leaking of clinical trial results in the U.S. Conflict-of-interest scandal facing physicians in the U.S.; Response of physicians on questions of drug performance.

  • Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial. Faries, Douglas; Ascher-Svanum, Haya; Phillips, Glenn; Nyhuis, Allen W.; Sugihara, Tomoko; Stauffer, Virginia; Kinon, Bruce J. // BMC Medical Research Methodology;2012, Vol. 12 Issue 1, p142 

    Background: Little is known about the specific reasons for antipsychotic discontinuation or continuation from patients' or clinicians' perspectives. This study aimed to assess the construct validity of 2 new measures of the Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a...

  • Let's Bring the Trial to the Subject! Hynes, Tim // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p58 

    Focuses on the compliance and retention issues in a clinical trial. Assessment of the typical response to recruitment and retention problems; Visitation of the subject in the comfort and privacy of the home; Continuation of in-home visits performed by a qualified homecare agency; Consideration...

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics